Table 2 |
||||||||||
|
Summary of the literature: Frequency of MSI in ovarian cancer. The total number of MSI, the number of MS markers used for the analysis and the number of MSI per histological subtype (if mentioned) is given for each study. |
||||||||||
|
MSI |
MS markers |
Histology |
||||||||
|
NCI-CP |
total |
SE |
EN |
CC |
MU |
MM |
PD |
|||
|
|
||||||||||
|
Helleman et al. |
0/75 |
(0%) |
2 |
2 |
0/36 (0%) |
0/13 (0%) |
0/3 (0%) |
0/10 (0%) |
0/8 (0%) |
0/3 (0%) |
|
Mesquita et al.2005 |
0/34 |
(0%) |
1 |
2 |
0/26 (0%) |
- |
0/8 (0%) |
- |
- |
- |
|
Gifford et al. 2004 |
2/138 |
(1%) |
3 |
6 |
Not mentioned |
|||||
|
Catasus et al. 2004 |
5/54 |
(9%) |
5 |
5 |
EN, CC and MM histology |
|||||
|
Cai et al.2004 |
6/42 |
(14%) |
5 |
5 |
- |
- |
6/42 (14%) |
- |
- |
- |
|
Liu et al.2004 |
15/74 |
(20%) |
4 |
4 |
- |
15/74 (20%) |
- |
- |
- |
- |
|
Singer et al.2004 |
6/75 |
(8%) |
5 |
11 |
5/53 (9%) |
1/14 (7%) |
0/3 (0%) |
0/5 (0%) |
- |
- |
|
Geisler et al.2003 |
21/125 |
(17%) |
5 |
6 |
10/69 (14%) |
6/22 (27%) |
0/4 (0%) |
2/9 (22%) |
- |
1/2 (50%) |
|
Watanabe et al. 2001 |
2/24 |
(8%) |
5 |
10 |
Not mentioned |
|||||
|
Sood et al. 2001 |
13/109 |
(12%) |
5 |
14 |
Not mentioned |
|||||
|
Gras et al.2001 |
7/76 |
(9%) |
5 |
10 |
0/17 (0%) |
1/48 (2%) |
1/8 (13%) |
0/2 (0%) |
0/6 (0%) |
- |
|
Buller et al. 2001 |
22/56 |
(39%) |
5 |
6 |
Not mentioned |
|||||
|
Chiaravalli et al.2001 |
3/16 |
(19%) |
2 |
3 |
0/8 (0%) |
1/2 (50%) |
- |
2/4 (50%) |
- |
0/2 (0%) |
|
Ohwada et al.2000 |
15/61 |
(25%) |
1 |
5 |
4/32 (13%) |
- |
- |
11/29 (38%) |
- |
- |
|
Allen et al.2000 |
1/25 |
(4%) |
2 |
4 |
1/16 (6%) |
0/2 (0%) |
0/2 (0%) |
0/1 (0%) |
- |
0/4 (0%) |
|
Colella et al. 1998 |
3/20 |
(15%) |
0 |
3 |
Not mentioned |
|||||
|
Sood et al. 1997 |
13/78 |
(17%) |
1 |
9 |
Not mentioned |
|||||
|
Sood et al. 1996 |
11/68 |
(16%) |
1 |
9 |
34 serous and 34 not serous |
|||||
|
Tangir et al.1996 |
2/31 |
(6%) |
0 |
13 |
2/31 (6%) |
- |
- |
- |
- |
- |
|
Arzimanoglou et al. 1996 |
11/90 |
(12%) |
1 |
3 |
Not mentioned |
|||||
|
Fujita et al.1995 |
7/44 |
(16%) |
0 |
4 |
2/22 (9%) |
5/10 (50%) |
0/4 (0%) |
0/8 (0%) |
- |
- |
|
|
||||||||||
|
Total |
165/1315 |
(13%) |
24/310 (8%) |
29/185 (16%) |
7/74 (9%) |
15/68 (22%) |
0/14 (0%) |
1/11 (9%) |
||
|
|
||||||||||
|
Abbreviations: SE serous, EN endometrioid, CC clear cell, MU mucinous, MM mixed mullerian, PD poorly differentiated, - not present, MS microsatellite, NCI-CP National Cancer Institute Consensus Panel. |
||||||||||
|
Helleman et al. BMC Cancer 2006 6:201 doi:10.1186/1471-2407-6-201 |
||||||||||
